Drug Trial Radar · NCT00335101
Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography
Last checked: Nov 20, 2026Latest source record: Apr 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jun 2006
Primary completion
Not stated
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- First posted
- Jun 8, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to evaluate and compare the effects on kidney function of three iodinated contrast media (CM) in patients at risk of kidney damage evaluating serum creatinine (Scr) concentrations up to three days after CM administration.
Conditions
- Coronary Artery Disease (CAD)
- Renal Impairment
- Diabetes Mellitus
Interventions
Iodixanol, Ioversol, IopromideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary endpoint:
- Maximum peak increase in SCr from baseline up to day 3.
- Secondary endpoints:
- Change in SCr from baseline to day 2 and to day 3
- Number of subjects with contrast-induced nephropathy (CIN)
- Quality of diagnostic information
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
GE Healthcare
Princeton, New Jersey
GE Healthcare
Munich, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.